Boehringer Ingelheim Marketed Drugs for Off-Label Uses
Boehringer Ingelheim is just the latest pharmaceutical company to pay millions of dollars to settle allegations of off-label drug marketing schemes.
The Germany-based company has reportedly agreed to pay $95 million over claims that they marketed Aggrenox, Combivent, Atrovent for non-FDA approved uses and promoted Micardis at unapproved doses.
Aggrenox, Combivent, Atrovent, and Micardis
- Approved to prevent secondary strokes.
- Marketed off-label for myocardial infarction and peripheral vascular disease.
- Approved to treat bronchospasm in patients with chronic obstructive pulmonary disease.
- Marketed off-label for use prior to using a bronchodilator.
- Approved to treat high blood pressure.
- Marketed off-label for treatment of early diabetic kidney disease.
- Approved to treat chronic obstructive pulmonary disease.
- Promoted at doses higher than those covered by federal health care programs.
Contact an Experienced Pharmaceutical Industry Attorney
Thomas J. Henry are leaders in the area of drug and product liability litigation. Our Defective Drug and Products Division have extensive knowledge and resources in order to represent our clients efficiently and aggressively. The Defective Drug and Products Division represent a multitude of people who are battling against manufacturers of medical devices and/ or defective pharmaceuticals.
If you or a loved one have been injured by or have developed serious side-effects from the use of a drug or pharmaceutical product, contact Thomas J. Henry immediately. We are available 24/7, nights and weekends.